ProMIS Neurosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMN research report →
About the company
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins.
- CEO
- Neil K. Warma
- IPO
- 2007
- Employees
- 7
- HQ
- Toronto, ON, CA
Price Chart
- Market Cap
- $17.46M
- P/E
- -0.57
- P/S
- 0.00
- P/B
- 1.44
- EV/EBITDA
- 1.13
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -237.99%
- ROIC
- -68.02%
- Revenue
- $0 · 0.00%
- Net Income
- $-39,719,147 · -1529.33%
- EPS
- $-22.61 · -922.18%
- Op Income
- $-40,167,308
- FCF YoY
- -3.45%
- 52W High
- $39.75
- 52W Low
- $6.27
- 50D MA
- $10.68
- 200D MA
- $11.76
- Beta
- -0.21
- Avg Volume
- 35.67K
Get TickerSpark's AI analysis on PMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 26 | WYMAN WILLIAM W | other | 11,000 |
| May 20, 26 | WYMAN WILLIAM W | other | 5,500 |
| May 20, 26 | Williams Eugene | other | 11,000 |
| May 20, 26 | Williams Eugene | other | 5,500 |
| May 20, 26 | Warma Neil K | other | 160,000 |
| May 20, 26 | Shafmaster Madge K. | other | 11,000 |
| May 20, 26 | Shafmaster Madge K. | other | 5,500 |
| May 20, 26 | Cashman Neil | other | 50,000 |
| May 20, 26 | Milbury Max A. | other | 18,167 |
| May 20, 26 | Mandel-Brehm Josh | other | 11,000 |
Our PMN coverage
Recent articles, reports, and earnings notes.
No research on PMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMN report →Similar companies
Peers in the same neighborhood.